Additional Proxy Soliciting Materials (definitive) (defa14a)
09 Décembre 2022 - 2:02PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Schedule 14A
Proxy Statement Pursuant to Section 14(a) of the
Securities Exchange Act of 1934
(Amendment No. )
Filed by the Registrant ☒
Filed by a party other than the Registrant ☐
Check the appropriate box:
| ☐ | Preliminary Proxy Statement |
| ☐ | Confidential, for Use of the Commission Only (as permitted
by Rule 14a-6(e)(2)) |
| ☐ | Definitive Proxy Statement |
| ☒ | Definitive Additional Materials |
| ☐ | Soliciting Material under § 240.14a-12 |
ACTINIUM PHARMACEUTICALS,
INC.
(Name of Registrant as Specified In Its Charter)
(Name of Person(s) Filing Proxy Statement,
if other than the Registrant)
Payment of Filing Fee (Check all boxes that apply):
| ☐ | Fee paid previously with preliminary materials. |
| ☐ | Fee computed on table in exhibit required by Item 25(b) per
Exchange Act Rules 14a- 6(i)(1) and 0-11 |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
December 8, 2022
ACTINIUM PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
001-36374 |
|
74-2963609 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(IRS Employer
Identification No.) |
275
Madison Avenue, 7th
Floor, New York, NY 10016
(Address of Principal Executive Offices)
Registrant’s telephone number: (646) 677-3870
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class |
|
Trading Symbol(s) |
|
Name of each exchange on which
registered |
Common Stock, par value $0.001 per share |
|
ATNM |
|
NYSE American |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 8.01 Other Events.
On December 8, 2022, Actinium Pharmaceuticals,
Inc. (“Actinium” or the “Company”) announced that the Company’s 2022 Annual Meeting of Stockholders, originally
scheduled for 9:30 a.m. (Eastern Time) on December 8, 2022, has been adjourned to allow for more time for stockholders to vote. The
meeting has been scheduled to reconvene at 9:30 a.m. (Eastern Time) on December 30, 2022, at The Garden City Hotel, 45 Seventh St, Garden
City, NY 11530.
During the period of the adjournment, the Company
will continue to solicit proxies from its stockholders with respect to the proposals set forth in the Company’s proxy statement.
Proxies previously submitted in respect to the Annual Meeting will be voted at the reconvened meeting unless properly revoked.
Any stockholders who have not yet voted may do
so before December 29, 2022 at 11.59 p.m. (Eastern Time). Stockholders of record may vote via the Internet at www.AALvote.com/atnm,
by telephone at 1-866-804-9616 or by mail by following the instructions on the proxy card. Beneficial stockholders can vote via the Internet, phone or mail by following the instructions received from their respective holders of record.
Any stockholders who have questions, need additional
material, or need assistance in voting their shares may contact the firm assisting the Company in the solicitation of proxies, Alliance
Advisors, LLC, by calling them at 1-877-777-2857 or writing them at 200 Broadacres Drive, 3rd Fl., Bloomfield, NJ 07003.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
Actinium Pharmaceuticals, Inc. |
|
|
Date: December 9, 2022 |
/s/ Sandesh Seth |
|
Name: Sandesh Seth |
|
Title: Chairman and Chief Executive Officer |
2
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Mar 2024 à Avr 2024
Actinium Pharmaceuticals (AMEX:ATNM)
Graphique Historique de l'Action
De Avr 2023 à Avr 2024